ClinConnect ClinConnect Logo
Search / Trial NCT04457544

Spontaneous Coronary Artery Dissection National Swiss Registry

Launched by DR. SOPHIE DEGRAUWE · Jun 30, 2020

Trial Information

Current as of August 26, 2025

Recruiting

Keywords

ClinConnect Summary

The Spontaneous Coronary Artery Dissection National Swiss Registry, also known as the SwissSCAD registry, is a research study focused on understanding a condition called spontaneous coronary artery dissection (SCAD). This condition mainly affects younger women who usually don’t have typical heart disease risk factors. SCAD can lead to serious heart problems, like heart attacks or even sudden cardiac arrest. The goal of this study is to learn more about how SCAD develops, its outcomes, and the different treatments available.

If you're an adult aged 18 or older and have been diagnosed with SCAD recently or within the last five years, you might be eligible to participate. To join the study, you would need to agree to take part by signing an informed consent form. Participants will be monitored over time, helping researchers gather important information about SCAD. This study is a chance to contribute to a better understanding of SCAD, which is still not very well known, and to help improve care for future patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subject is ≥18 years of age.
  • Patient presenting newly diagnosed SCAD or diagnosed with SCAD within the last 5 years.
  • Subject must be willing to sign a Patient Informed Consent (PIC).
  • Exclusion Criteria:
  • Patient unwilling or unable to provide informed consent.
  • Patients with atherosclerotic or iatrogenic coronary dissection.

About Dr. Sophie Degrauwe

Dr. Sophie Degrauwe is a distinguished clinical trial sponsor with a robust background in medical research and a commitment to advancing healthcare through innovative studies. With extensive experience in overseeing clinical trials across various therapeutic areas, Dr. Degrauwe emphasizes rigorous scientific methodology, patient safety, and ethical standards. Her leadership fosters collaboration among multidisciplinary teams, ensuring that trials are conducted efficiently and effectively to generate reliable data that contributes to the development of new therapies. Dr. Degrauwe's dedication to enhancing patient outcomes positions her as a key figure in the clinical research landscape.

Locations

Geneva, , Switzerland

Patients applied

0 patients applied

Trial Officials

Sophie Degrauwe, Dr

Principal Investigator

Hopitaux universitaires de Geneve

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials